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Abstract
Background: The WHODAS-2 is a disability assessment instrument based on the conceptual framework of the 
International Classification of Functioning, Disability, and Health (ICF). It provides a global measure of disability and 7 
domain-specific scores. The aim of this study was to assess WHODAS-2 conceptual model and metric properties in a 
set of chronic and prevalent clinical conditions accounting for a wide scope of disability in Europe.
Methods: 1,119 patients with one of 13 chronic conditions were recruited in 7 European centres. Participants were 
clinically evaluated and administered the WHODAS-2 and the SF-36 at baseline, 6 weeks and 3 months of follow-up. 
The latent structure was explored and confirmed by factor analysis (FA). Reliability was assessed in terms of internal 
consistency (Cronbach's alpha) and reproducibility (intra-class correlation coefficients, ICC). Construct validity was 
evaluated by correlating the WHODAS-2 and SF-36 domains, and comparing known groups based on the clinical-
severity and work status. Effect size (ES) coefficient was used to assess responsiveness. To assess reproducibility and 
responsiveness, subsamples of stable (at 6 weeks) and improved (after 3 moths) patients were defined, respectively, 
according to changes in their clinical-severity.
Results: The satisfactory FA goodness of fit indexes confirmed a second order factor structure with 7 dimensions, and a 
global score for the WHODAS-2. Cronbach's alpha ranged from 0.77 (self care) to 0.98 (life activities: work or school), 
and the ICC was lower, but achieved the recommended standard of 0.7 for four domains. Correlations between global 
WHODAS-2 score and the different domains of the SF-36 ranged from -0.29 to -0.65. Most of the WHODAS-2 scores 
showed statistically significant differences among clinical-severity groups for all pathologies, and between working 
patients and those not working due to ill health (p < 0.001). Among the subsample of patients who had improved, 
responsiveness coefficients were small to moderate (ES = 0.3-0.7), but higher than those of the SF-36.
Conclusions: The latent structure originally designed by WHODAS-2 developers has been confirmed for the first time, 
and it has shown good metric properties in clinic and rehabilitation samples. Therefore, considerable support is 
provided to the WHODAS-2 utilization as an international instrument to measure disability based on the ICF model.
Background
A common, international, and interdisciplinary frame-
work of disability measurement is important to develop
effective and comparable policy and practice options[1,2].
During the last decades, the definition of disability has
moved from the biomedical and social models to the
biopsychosocial model, emphasizing the dynamic and
bidirectional relations between a health condition and
contextual factors (personal and environmental). In order
to reach a universally accepted conceptual framework to
define and classify disability[3,4], the World Health Orga-
nization (WHO) developed the International Classifica-
tion of Functioning, Disability, and Health (ICF)[5,6]. In
the ICF, disability is described as "a difficulty in function-
ing at the body, person, or societal levels, in one or more
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l i f e  d o m a i n s ,  a s  e x p e r i e n c e d  b y  a n  i n d i v i d u a l  w i t h  a
health condition in interaction with contextual factors"[7].
As part of the ongoing development of the ICF concep-
tual model, the World Health Organization Disability
Assessment Schedule 2.0 (WHODAS-2) was created in
1998 (as a substantially reviewed version of the WHO-
DAS[8]) to assess disability based on the ICF model[9].
There exist other tools that have traditionally been used
to measure disability, such as the Indexes of activities of
daily living (ADLs)[10], the Functional Limitations Pro-
file[11], or the Functional Status Questionnaire[12]; and
also a battery of instruments developed focusing on spe-
cific populations (i.e., the Late Life Function and Disabil-
ity Instrument for elders[13], and the Functional
Disability Inventory for children[14]). Nevertheless, none
of them has been developed with the clear ICF biopsy-
chosocial conceptual model.
Previous studies have evaluated the metric properties
of the WHODAS-2 in specific samples, such as arthri-
tis[15], systemic sclerosis[16], psychotic disorders[17],
hearing loss[18], stroke[19], ankylosing spondylitis;[20],
depression and low back pain[21], schizophrenia[22], and
patients in rehabilitation[23], among others[24]. How-
ever, data regarding the validity of the WHODAS-2
across a range of diagnoses, settings, and countries is
missing. On the other hand, these studies were generally
focused on reliability, validity or responsiveness, but the
underlying factor structure has almost never been
assessed. Available evidence confirming the original
structure is only provided for a modified version (i.e. the
WHODAS used in the WMH surveys initiative[25,26]),
while findings from WHODAS-2 exploratory factor anal-
ysis were not consistent with the proposed measurement
model [23,24]. Thus, a comprehensive evaluation of the
conceptual model and metric properties of the WHO-
DAS-2 is needed.
The 'Measuring Health and Disability in Europe: Sup-
porting policy development-MHADIE'[8,27] is a Euro-
pean multidisciplinary project which has as one of its
main objectives the evaluation of the ICF model and
related instruments in clinical and rehabilitative settings.
As part of this international project, the aim of the pres-
ent study was to assess the WHODAS-2 conceptual
model and metric properties in a set of chronic and prev-
alent clinical conditions, both physical and mental disor-
ders, accounting for a wide scope of disability in Europe.
Methods
Design
The MHADIE is an observational, longitudinal, multi-
centric study of consecutive patients with different
chronic conditions in 7 European centres from Czech
Republic, Germany, Italy, Slovenia, and Spain. Evalua-
tions were made at baseline and at 6 weeks and 3 months
of follow-up. Background characteristics such as age, sex,
education or occupational status were collected from all
subjects. In addition, patients were clinically evaluated
with disease-specific severity scales, and with stan-
dardised instruments measuring disability and quality of
life.
Sample
Patients had to be over 18 years old and meet the diagno-
sis criteria of one of the following conditions: bipolar dis-
order, depression, osteoarthritis, osteoporosis,
rheumatoid arthritis, chronic widespread pain (CWP),
low back pain (LBP), ischemic heart disease (IHD),
migraine, Parkinson disease, multiple sclerosis, traumatic
brain injury (TBI), or stroke. Sample size was based on
recommendations for exploratory and confirmatory fac-
tor analyses (at least 20 participants per variable), and
balanced by disorder. Ethical approvals from each institu-
tional ethics committee and informed consent from each
participant were obtained.
Measurement instruments
The World Health Organization Disability Assessment 
Schedule-2
The WHODAS-2 contains 36 items on functioning and
disa bility wit h a r ecall period of 30 da ys[8] covering 7
domains: Understanding and Communicating (6 items),
Getting around (5 items), Self-care (4 items), Getting along
with others (5 items), Life activities: household (4 items),
Life activities: work/school (4 items), and Participation in
society (8 items). Response options go from 1 (no diffi-
culty) to 5 (extreme difficulty or can not do).
WHODAS-2 scores are computed for each domain by
adding the item responses (the score computation allows
for up to 30% of missing items per domain) and trans-
forming them into a range from 0 to 100, with higher
scores indicating higher levels of disability. A global score
is also calculated from all the items (36) or from all except
the Life activities ones -work/school- when people does
not apply for this domain (32 items). When less than 50%
of items were missing, mean substitution (by domain)
was used for imputation.
The Short Form-36 Health Survey (SF-36)
The SF-36 is a generic Health Related Quality of Life
(HRQL) instrument measuring 8 domains: Physical Func-
tioning, Role Physical, Bodily Pain, General Health, Vital-
ity, Social Functioning, Role Emotional, and Mental
Health[28]. Items are transformed into scores from 0
(worst possible health state) to 100 (best). A weighted
addition of these domains allows the computation of two
summary scores: Physical and Mental Components Sum-
maries (PCS & MCS)[29,30]. Scores were not computed
f o r  t h o s e  i n d i v i d u a l s  w i t h  m o r e  t h a n  5 0 %  o f  m i s s i n g
items per domain. All patients were administered the SF-Garin et al. Health and Quality of Life Outcomes 2010, 8:51
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36 version 1, except those with bipolar disorder or
depression, that completed version 2. Main differences
between the two versions concern the number of
response options of the Role domains, which were incre-
mented from 2 to 5; and minor changes in the mental
health and vitality dimensions (from 6 to 5 response
options)[31].
Disease-specific severity scales
As shown in Table 1, several different scales were used to
evaluate the severity of the health conditions [32-40]. A
consensus on the best way of classifying patients into dif-
ferent severity groups in order to evaluate differences on
WHODAS-2 scores was reached between researchers
and the clinical specialist responsible of the patients'
management. Criteria used for classifying patients as
being mild, moderate or severe are defined in Table 1.
The sample sizes of the final groups are also shown.
Questionnaires were either self-administered or inter-
viewer-administered. Proxy versions were occasionally
used with those patients unable to respond due to the
severity of the health condition leading to cognition or
communication difficulties, such as aphasia.
Analytical strategy
Exploratory and Confirmatory factor analyses (EFA &
CFA) were performed to assess WHODAS-2 structure
Table 1: Health condition, severity scales and criteria to make groups.
Health Condition Severity Scales Theoretical Range Groups' criteria Severity Groups, n
Bipolar Disorder Young Rating Scale of Mania (YRSM)
&Hamilton Depression Rating Scale (HDRS)
YRSM_ 0-60 
HDRS_ 0 - 52
Eutimic if
YRSM < 7 and
HDRS < 9
Eutimic, 78 
No eutimic, 36
Depression International Classification 
of Disease (ICD-10)
__ Clinicians
criteria
Mild, 36 
Moderate, 30 
Severe, 19
Osteoarthritis --- --- --- ---
Osteoporosis Magnitude of the 
problems in functioning
0-10 Terciles (0-1)
(2-3)
(4-10)
Mild, 41 
Moderate, 27 
Severe, 17
Rheumatoid 
Arthritis
Criteria for the 
Classification of Global 
Functional Status (ACR)
Class I-IV I,
II-III,
and IV
Mild, 5 
Moderate, 16 
Severe, 2
Chronic 
Widespread 
Pain (CWP)
Pain intensity rate 0 - 10 Terciles (0-4)
(5-6)
(7-10)
Mild, 15 
Moderate, 14 
Severe, 13
Low Back 
Pain (LBP)
Pain intensity rate 0 - 10 Terciles (0-3)
(4-6)
(7-10)
Mild, 42 
Moderate, 44 
Severe, 24
Ischemic Heart 
Disease (IHD)
New York Heart 
Association Criteria 
(NYHA)_ IV classes
Class: I-IV I
II
III
Mild, 12 
Moderate, 71 
Severe, 17
Migraine Migraine Disability 
Assessment 
Questionnaire (MIDAS)
4 groups Minimal-mild,
moderate,
and severe
Mild, 27 
Moderate, 29 
Severe, 46
Parkinson Disease Hoehn and Yahr scale 
(H&Y)_5 groups
5 stages 1,
2,
and ≥ 3
Mild, 13 
Moderate, 54 
Severe, 26
Multiple Sclerosis Expanded Disability Status
 Scale (EDSS)
0-10 (0-2.5)
(3-5)
(5.5-10)
Mild, 43 
Moderate, 36 
Severe, 21
Traumatic Brain 
Injury (TBI)
Functional Independence 
Measure (FIM)
18 - 126 < 116;
116-126;
and ≥ 126
Mild, 36 
Moderate, 33 
Severe, 31
Stroke < 47;
47-63;
and ≥ 63
Mild, 78 
Moderate, 24 
Severe, 2†
†Excluded from analyses as for most WHODAS-2's scores information for just one of the two individuals was available.Garin et al. Health and Quality of Life Outcomes 2010, 8:51
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and dimensionality. The global sample at baseline was
divided into two random sub-samples, stratifying by
pathology and severity group (n1 = 533 and n2 = 547). As
WHODAS-2 responses are categorical variables, the fac-
torial analyses were based on polychoric correlations, and
robust-weighted least squares estimators were
used[41,42]. The first subsample (n1) was used to perform
an EFA with oblique (quartimin) rotation[43]. The factor
structure obtained by the EFA was assessed on the CFA
using the second subsample (n2). The model to be con-
firmed was also imposed to have a general (global) sec-
ond order factor; related with the specific factors. On this
type of models, the general factor (2nd level) explains the
correlation among specific factors (first level)[44]. Good-
ness-of-fit was measured by the Root Mean Square Error
of Approximation (RMSEA, adequate if below 0.08), and
the Comparative Fit Index (CFI) and Tucker-Lewis Index
(TLI), which are recommended to be over 0.95[45]. These
analyses were conducted with MPlus 4.2 and missing val-
ues were considered missing at random[45].
Distribution of WHODAS-2 and SF-36 scores was eval-
uated for the whole sample: means (SD), observed range,
percentage of patients with missing domain scores, and
floor and ceiling effects (proportion of patients with the
worst and best possible score, respectively). Reliability
was assessed in terms of internal consistency and repro-
ducibility. The former was evaluated with the Cronbach's
alpha coefficients computed with the whole sample at
baseline[46]. To assess reproducibility, a sub-sample of
stable patients (their clinical-severity not having changed
at the six weeks evaluation) was identified. Concordance
in the scores of stable patients was estimated with the
Intra-class Correlation Coefficient (ICC)[47].
Construct validity was assessed by 2 different
approaches: the Multitrait Multimethod (MTMM)
Matrix[48] and known groups. Taking into account simi-
l a r i t y  o n  c o n t e n t ,  P e a r s o n  c o r r e l a t i o n s  ( M T M M )  w e r e
previously hypothesized to be moderate (0.4-0.6)
between some of the WHODAS-2 domains and the SF-
36 scores. Known groups were defined in two ways: first,
based on the severity of the health condition (mild, mod-
erate, and severe) and second, based on whether the
patients were working or not due to their health condi-
tion (i.e. those who were on sick leave or who reported "ill
health" as the main reason for not working for pay).
Means scores were compared with ANOVA and the mag-
nitude of the difference between extreme groups was
measured by an Effect Size coefficient (difference in mean
scores between groups/pooled SD)[49].
To assess sensitivity to change, the only conditions
included were those where an improvement was expected
over the study period (all except bipolar disorder,
osteoarthritis, Parkinson disease, and multiple-sclerosis).
Patients suffering from any of these pathologies with a
positive change in the severity measure after 3 months
were considered "clinically improved". Paired mean com-
parisons (t-test) between baseline and the third evalua-
tion of these patients were conducted. In this case, the
magnitude of the difference was also assessed with ES
coefficients, but computed dividing the difference in the
scores between the two evaluations by the SD at baseline.
An ES > 0.8 is considered high, one of 0.5 moderate, and
one close to 0.2 is considered low[50].
Results
Sample characteristics are shown in Table 2. More than
half of the subjects were not working for pay (57.8%), and
49% of them (n = 327) reported a main reason: 184
retired and 75 with 'ill health'. The EFA showed the 7-fac-
tor model to be the most appropriate structure (Table 3).
Most of the WHODAS-2 items (86%) presented the high-
est loading with their corresponding factor. Moreover,
the highest factor loadings of each item was above 0.5 in
75% of the cases. Results of CFA presented acceptable
goodness of fit indexes: CFI and TLI above the standard
0.95 (0.975 and 0.973), and RMSEA (0.127); and sup-
ported the 7 domains proposed, as well as the global
score.
The distribution characteristics and reliability coeffi-
cients of WHODAS-2 and SF-36 scores are reported in
Table 4. The global WHODAS-2 mean score was 24.8(SD
= 19.3), ranging from 0.0 to 93.5. The proportion of miss-
ing values was lower than 16% for most of the WHO-
DAS-2 domains (with the exception of 'life activities:
work or school', which was not responded by 50.2% of the
sample). The floor effect was not relevant, but quite a
high ceiling effect was present in almost all domains,
especially for 'Self-care' (53.6%). Cronbach's alpha was
above 0.7 for all WHODAS-2 scales, being the highest for
the two domains of 'Life activities' and for the Global
score (0.94-0.98). Last column of Table 4 shows the
results on test-retest evaluation of reproducibility. The
ICC was lower than Cronbach's alpha coefficient, but
achieved the recommended standard of 0.7 for 4 of the
domains.
Table 5 presents the MTMM Matrix, where the correla-
tions hypothesized as moderate (in bold) were confirmed.
The global WHODAS-2 score was moderately correlated
with most of the scores of the SF-36, with the main excep-
tion of 'Bodily pain', which presented quite low correla-
tions with all the WHODAS-2 domains. The
'Participation in society' domain presented moderate to
high correlations (0.4-0.6) with all the SF-36 dimensions.
Moreover, moderate correlations not previously hypothe-
sized were found between 'Life activities at work or
school' and 'Social functioning' from the SF-36(0.5), and
between 'Life activities: household' and three of the SF-36Garin et al. Health and Quality of Life Outcomes 2010, 8:51
http://www.hqlo.com/content/8/1/51
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Table 2: Socio-demographic characteristics of global sample, and the reproducibility and improvement sub-samples.
All patients baseline, n = 1190 Stable at 6 weeks, n = 404 Improved at 3 months, n = 131
Sex, n (%) **
Male 520 (43.8%) 205 (50.7%) 45 (34.4%)
Female 666 (56.2%) 199 (49.3%) 86 (65.6%)
Age, mean (SD)
52.7 (15.6) 53.4 (16.0) 54.5 (14.5)
Marital status, n (%)
Never married 233 (20.0%) 71 (17.9%) 20 (15.6%)
Currently married 659 (56.6%) 247 (62.4%) 68 (53.1%)
Separated 40 (3.4%) 7 (1.8%) 4 (3.1%)
Divorced 73 (6.3%) 22 (5.6%) 14 (10.9%)
Widowed 92 (7.9%) 30 (7.6%) 14 (10.9%)
Cohabiting 68 (5.8%) 19 (4.8%) 8 (6.3%)
Highest level of education, n (%) *
No formal schooling 4 (0.4%) 1 (0.3%) 1 (0.8%)
Less than primary school 28 (2.5%) 5 (1.3%) 4 (3.2%)
Primary school completed 241 (21.9%) 90 (22.8%) 39 (31.5%)
Secondary school completed 256 (23.2%) 106 (26.9%) 39 (31.5%)
High school (or equivalent) completed 281 (25.5%) 108 (27.4%) 16 (12.9%)
College/University completed 266 (24.1%) 79 (20.1%) 23 (18.5%)
Postgraduate degree completed 26 (2.4%) 5 (1.3%) 2 (1.6%)
Current job, n (%) *
Government employee 132 (11.5%) 43 (11.1%) 20 (15.4%)
Non-government employee 221 (19.3%) 69 (17.8%) 26 (20.0%)
Self-employed 99 (8.6%) 37 (9.6%) 13 (10.0%)
Employer 32 (2.8%) 11 (2.8%) 2 (1.5%)
Not working for pay 663 (57.8%) 227 (58.7%) 69 (53.1%)
Health conditions, n (%) *
Bipolar 114 (9.6%) 4 (1.0%) ---
Depression 83 (7.0%) 15 (3.7%) 19 (14.5%)
Musculo-skeletal conditions 297 (25.0%) 57 (14.1%) 27 (20.6%)
Osteoarthritis 19 (1.6%) --- ---
Osteoporosis 87 (7.3%) 17 (29.8%) 4 (14.8%)
Rheumatoid Arthritis 24 (2.0%) 11 (19.3%) 3 (11.1%)
Chronic Widespread Pain 
(CWP)
49 (4.1%) 12 (21.1%) 9 (33.3%)
Low Back Pain (LBP) 118 (9.9%) 17 (29.8%) 11 (40.7%)
Ischemic Heart Disease (IHD) 100 (8.4%) 76 (18.8%) 12 (9.2%)
Migraine 102 (8.6%) --- 28 (21.4%)
Parkinson Disease 96 (8.1%) 48 (12.4%) ---
Multiple-Sclerosis 100 (8.4%) 37 (9.2%) ---
Traumatic Brain Injury (TBI) 100 (8.4%) 50 (12.4%) 1 (0.8%)
Stroke 198 (16.6%) 67 (16.6%) 44 (33.6%)
* p < 0.05 (between the distribution of patients included and not included on that sub-sample)Garin et al. Health and Quality of Life Outcomes 2010, 8:51
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Table 3: Quartimin rotated loadings* of the Exploratory Factor Analysis with 7 Factors.
1234567
Understanding & Communicating. D1
concentrating 0.54 -0.26 -0.17 0.17 0.10
remembering 0.64 -0.10 0.18 0.11
finding solutions 0.56 -0.12 0.20 0.12 0.24
learning new task 0.64 0.12 0.15
understanding 0.73 0.10 0.15 -0.12
conversation 0.50 0.41
Getting around. D2
standing 0.73 0.28 0.12
standing up 0.25 -0.35 0.10 0.57 -0.26
moving around 0.15 -0.39 0.27 0.41 0.10 0.13
getting out of home -0.4 0.35 0.20 0.25 0.23 0.19
walking -0.16 -0.14 0.59 0.34 0.20
Self Care. D3
washing -0.66 0.15 -0.34
dressing -0.79 0.13 -0.19
eating -0.72 -0.27 0.16 0.10
staying by yourself -0.20 -0.44 0.14 0.35 -0.17
Getting along with people. D4
dealing with people unknown 0.24 0.76
maintaining friendship 0.17 0.69 -0.17
getting along with people close 0.19 0.16 -0.17 0.43
make new friends 0.19 0.10 0.75
sexual activities -0.20 -0.13 0.09 0.12 0.29 -0.36
Life activities: household. D5.1
household responsibilities 0.77 -0.17
doing household tasks well 0.90
doing housework needed 0.86 -0.11
household work done quickly 0.10 0.18 0.84
Life activities: work or school. D5.2
day to day work/school 0.11 0.11 -0.81
doing most important work well -0.11 -0.84
getting work done needed -0.90
getting work done quickly 0.14 -0.78
Participation in society. D6
problems in communities -0.10 -0.11 0.13 0.12 0.17 0.47 -0.29
problems because of barriers 0.14 0.32 0.27 -0.20
living with dignity 0.15 0.10 0.26 -0.17
time spend on health condition -0.16 -0.13 0.47 0.39
been emotionally affected 0.55 -0.11 0.15 0.21 -0.17
drain on financial resources 0.24 0.11 0.52 0.18 0.23 -0.29
problems for the family 0.49 -0.11 -0.36
problems doing things for relaxation 0.32 0.24 0.29 -0.11
*only factor loadings above 0.1 are shown.Garin et al. Health and Quality of Life Outcomes 2010, 8:51
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dimensions, 'Physical functioning' (0.6), 'Social function-
ing' (0.48), and 'Role physical' (0.47).
The WHODAS-2 global score showed statistically sig-
nificant differences among severity groups for all pathol-
ogies (Figure 1) with ES coefficients over 0.7 between
mild and severe groups, except for low back pain. Table 6
shows mean scores of the specific domains by each sever-
ity group. Three of the WHODAS-2 domains (Getting
along with people, Life activities household, and life
activities work or school) presented non-significant dif-
ferences among severity groups for more than half of the
pathologies. For physical disorders, in general no signifi-
cant differences across severity were observed in the
understanding and communicating domain, and the ES
coefficients were generally smaller than for the mental or
neurological conditions. The results showed that at least
4 of the 7 WHODAS-2 domains differ statistically by
severity groups for all conditions, except stroke. Most of
the mean differences between extreme groups presented
a ES coefficient > 0.5.
Almost all the WHODAS-2 scores showed statistically
significant differences (p < 0.001) between working
patients and those not working due to ill health (Figure
2), and all except 2 presented an ES above 0.5. For the SF-
36 scores, only 3 out of 10 ES coefficients were moderate
or high.
Figure 3 shows the mean change of the WHODAS-2
scores and SF-36 component summaries among the sub-
sample of patients that had improved. The ES coefficients
were moderate for 2 WHODAS-2 domains: 'Life Activi-
ties: work or school' (ES = 0.47), and 'Participation in
Society' (ES = 0.66); and for the Global score (ES = 0.55).
For the rest of the scores the ES was less than 0.4.
Discussion
This study confirms the conceptual model of the WHO-
DAS-2, which has shown good metric properties among
patients with chronic conditions in Europe in the
MHADIE project: a very high reliability, good ability to
discriminate among known groups and adequate capacity
Table 4: Distribution of scores and reliability coefficients for the WHODAS-2 and SF-36 domains
Mean SD Observed Range Missing 
domain (%)
Floor (%) Ceiling (%) Cronbach's alpha ICC (n = 404)
WHODAS-2
Understanding and 
Communicating
17.9 20.9 (0.0 - 100.0) 2.7 0.6 29.1 0.88 0.612
Getting Around 27.8 27.1 (0.0 - 100.0) 2.8 1.0 25.4 0.80 0.197
Self Care 14.4 21.2 (0.0 - 100.0) 2.8 0.3 53.6 0.77 0.524
Getting along with 
people
18.9 23.3 (0.0 - 100.0) 5.0 1.2 36.1 0.81 0.642
Life Activities: household 37.7 34.4 (0.0 - 100.0) 13.3 11.1 24.8 0.94 0.680
Life Activities: work or 
school
37.9 38.1 (0.0 - 100.0) 50.2 19.8 27.3 0.98 0.690
Participation in Society 28.1 21.0 (0.0 - 91.7) 5.2 0.0 10.9 0.82 0.693
Global 24.8 19.3 (0.0 - 93.5) 15.2 0.0 3.6 0.95 0.738
SF-36
Physical Functioning 65.4 29.8 (0.0 - 100.0) 4.5 4.6 10.8 0.94† 0.88* 0.791
Role Physical 49.0 42.0 (0.0 - 100.0) 4.4 33.4 30.5 0.85† 0.96* 0.696
Role Emotional 60.3 41.0 (0.0 - 100.0) 5.0 22.6 43.2 0.87† 0.83* 0.556
Social Functioning 64.9 29.0 (0.0 - 100.0) 3.3 4.0 23.4 0.68† 0.78* 0.533
Mental Health 61.2 21.2 (0.0 - 100.0) 5.1 0.7 1.4 0.78† 0.87* 0.714
Bodily Pain 57.6 29.5 (0.0 - 100.0) 3.3 2.1 21.3 0.83† 0.88* 0.610
Vitality 50.9 21.8 (0.0 - 100.0) 5.0 1.8 0.8 0.84† 0.94* 0.684
General Health 53.4 21.3 (0.0 - 100.0) 5.6 0.9 0.5 0.82† 0.87* 0.759
PCS 42.0 11.2 (13.3 - 71.6) 8.0 --- --- --- --- 0.782
MCS 43.5 13.1 (-0.2 - 72.8) 8.0 --- --- --- --- 0.676
†SF-36 version 1 (TBI, IHD, Migraine, Parkinson, MS, stroke, musculoskeletal): n = 993
*SF-36 version 2 (bipolar y depression): n = 198G
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Table 5: Multitrait-multimethod matrix. Pearson correlation coefficients between the WHODAS-2 and the SF-36 scores.
WHODAS-2
Understanding & 
Communicating
Getting 
around
Self Care Getting along 
with people
Life activities: 
household
Life activities:
 work or school
Participation 
in society
Global
SF-36 Physical Functioning -0.13 -0.75 -0.40 -0.15 -0.61 -0.41 -0.55 -0.55
Role Physical -0.05 -0.46 -0.19 -0.03 -0.47 -0.34 -0.44 -0.36
Role Emotional -0.33 -0.42 -0.33 -0.31 -0.45 -0.45 -0.50 -0.53
Social Functioning -0.38 -0.49 -0.44 -0.44 -0.48 -0.50 -0.63 -0.65
Mental Health -0.50 -0.36 -0.42 -0.49 -0.38 -0.44 -0.54 -0.60
Bodily Pain -0.14 -0.38 -0.17 -0.05 -0.32 -0.174 -0.33 -0.29
Vitality -0.45 -0.45 -0.40 -0.42 -0.43 -0.36 -0.51 -0.57
General Health -0.38 -0.42 -0.33 -0.37 -0.35 -0.33 -0.49 -0.51
Correlations expected to be high or moderate are shown in bold type letter.
Pearson coefficients are negative because the two instruments scores, have the opposite direction.Garin et al. Health and Quality of Life Outcomes 2010, 8:51
http://www.hqlo.com/content/8/1/51
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to detect change over time. Therefore, these results sup-
port the adequacy of the WHODAS-2 to measure disabil-
ity in a wide range of physical and mental disorders.
The goodness of fit indices obtained with the CFA
models together with the high factor loadings confirmed
the 7 domain structure of WHODAS-2 and the global
score [44], as proposed by developers. Only some con-
cerns should be raised. The RMSEA wasn't below the
standard as recommended. CFA modification indexes
(data not shown) suggested that the structural model
behind data may be improved if some items from 'Partici-
pation in Society' domain were relocated on some of the
other factors. Nonetheless, accepting the original struc-
ture proposed by developers would improve comparabil-
ity with past and ongoing WHODAS-2 studies.
Therefore, we suggest using the structure of the WHO-
DAS-2 as it is now known, taking into account the expert-
based validity criteria originally applied and that, despite
the described concerns, our findings confirmed it on a
heterogeneous sample. Moreover, the structure is quite
consistent with previous results, both from specific popu-
lations[23,24] and from the modified version[25].
The low proportion of missing values suggests the easy
completion for a wide range of patients, indicating the
high feasibility of WHODAS-2. A great percentage of
missing data was only found at the domain of activities at
work or school (50.3%), which is clearly related with the
proportion of respondents neither working nor being stu-
dents. The moderate percentage of patients with the best
possible score in several domains suggests the possible
unsuitability of the WHODAS-2 to differentiate among
very low grades of disability. This may not be a limitation
for measuring disability on patient samples, but one
should be cautious when using it on other samples such
as general population, which has earlier shown a very
high ceiling effect[26]. Nonetheless, the distribution of
the 'Participation in society' score merits a comment. No
patient has the worst possible score (floor effect) and
presents the lowest ceiling effect (11%), indicating that
this domain is able to characterize a wide range of scenar-
ios and is perhaps reflective of the final common pathway
in which disability is manifested in the societal context.
The high internal consistency coefficients indicate
good reliability. All of them were above the standard pro-
posed for group comparisons (0.7) [51], which is consis-
tent with findings from previous
studies[23,15,19,21,22,24]. It is also remarkable that inter-
nal consistency coefficient for the global score reaches
the most strict standard recommended for individual
comparisons of 0.95. Reproducibility was acceptable, with
the exception of the 'Getting around' domain (ICC =
0.19). Due to the long test-retest period, patient's mobility
may have improved or worsened over 6 weeks, even
though disease severity did not change substantially. The
Figure 1 WHODAS-2 global score for each severity group by pathology. *no statistical significant difference. Mean and 95% confidence interval 
is shown. Effect Size (ES) coefficient among extreme groups.
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Table 6: WHODAS-2 domain specific scores by disorder, according to severity level.
Pathology (n) Understanding &
Communicating
Getting 
Around
Self 
Care
Getting along 
with people
Life Activities: 
household
Life Activities: 
work or school
Participation 
in Society
Bipolar ES = 1.03 ES = 0.69 ES = 1.43 ES = 0.85 ES = 0.56 ES = 1.97 ES = 1.27
Eutimic (78) 21.4 (19.6) 9.0 (12.3) 4.1 (8.5) 19.8 (20.5) 20.1 (24.8) 15.8 (22.2) 15.3 (15.4)
No eutimic (36) 44.0 (26.5)* 20.7 (24.4)* 23.3 (20.4)* 38.9 (26.1)* 34.7 (28.8)* 72.9 (40.0)* 37.2 (20.6)*
Depression ES = 1.44 ES = 1.24 ES = 1.82 ES = 1.61 ES = 0.56 ES = 0.75 ES = 1.5
Mild (36) 34.3 (20.1) 27.6 (21.9) 20.9 (21.5) 44.6 (23.1) 54.1 (30.4) 71.2 (38.2) 37.4 (15.0)
Moderate (30) 49.2 (19.5) 42.1 (24.5) 48.3 (22.0) 57.5 (28.9) 63.3 (33.3) 87.9 (18.5) 47.9 (13.3)
Severe (19) 66.8 (26.4)* 57.6 (27.7)* 60.5 (22.2)* 80.7 (21.2)* 72.1 (35.4) 94.9 (13.5) 61.6 (18.1)*
TBI ES = 1.21 ES = 1.12 ES = 1.22 ES = 1.1 ES = 0.96 ES = 1.59 ES = 1.49
Mild (36) 6.9 (10.6) 4.2 (12.2) 1.7 (5.1) 8.3 (15.6) 10.8 (18.4) 10.3 (18.0) 9.8 (15.2)
Moderate(33) 17.6 (19.1) 9.7 (15.1) 4.8 (10.3) 15.9 (16.4) 18.6 (20.1) 25.0 (30.1) 22.0 (16.1)
Severe (31) 27.6 (22.2)* 31.1 (32.2)* 22.7 (24.4)* 31.1 (25.3)* 36.6 (34.0)* 61.2 (42.2)* 39.4 (24.0)*
IHD ES = 0.89 ES = 1.21 ES = 1.09 ES = 0.44 ES = 0.89 ES = 0.69 ES = 1.28
Mild (12) 0.8 (2.9) 10.4 (19.8) 2.5 (8.7) 4.9 (6.6) 13.8 (35.0) 47.1 (50.4) 16.0 (13.9)
Moderate (71) 6.6 (9.5) 32.0 (29.0) 16.3 (18.6) 13.4 (12.3) 42.9 (43.0) 57.1 (43.1) 29.9 (16.9)
Severe (17) 11.5 (15.4)* 44.1 (32.4)* 26.5 (27.6)* 24.5 (24.2)* 63.3 (45.3) 52.4 (46.4) 37.3 (21.5)*
Migraine ES = 0.57 ES = 0.54 ES = 0.36 ES = 0.51 ES = 0.97 ES = 0.61 ES = 1.07
Mild (27) 10.8 (9.3) 9.1 (13.1) 4.1 (9.3) 10.1 (10.4) 18.5 (20.7) 20.5 (17.4) 15.7 (10.7)
Moderate (29) 21.9 (16.7) 15.5 (20.1) 10.7 (17.5) 14.8 (19.8) 34.6 (23.6) 30.8 (19.4) 24.6 (13.5)
Severe (46) 22.4 (24.3)] * 23.2 (25.6) * 8.9 (16.6) 20.0 (24.6) 43.3 (29.5)* 34.8 (22.5) * 31.2 (16.3)*
Parkinson ES = 0.67 ES = 1 ES = 1.05 ES = 0.54 ES = 0.07 ES = 0.48 ES = 0.91
Mild (13) 8.5 (10.1) 13.0 (20.6) 5.0 (8.7) 9.5 (11.4) 30.0 (22.4) 33.0 (32.8) 21.8 (13.8)
Moderate (54) 9.4 (9.2) 20.5 (20.6) 16.3 (19.5) 12.0 (12.7) 18.8 (22.1) 21.4 (19.9) 22.4 (15.2)
Severe (26) 19.8 (19.4)* 42.5 (33.0)* 31.9 (30.6)* 20.7 (23.8) 28.3 (27.5) 18.6 (28.4) 39.4 (21.4)*
Multiple sclerosis ES = 0.42 ES = 3.08 ES = 1.34 ES = 0.48 ES = 1.22 ES = 1.11 ES = 1.71
Mild (43) 2.4 (5.9) 4.4 (8.9) 1.6 (5.7) 4.6 (9.5) 8.6 (13.4) 4.9 (9.8) 8.7 (9.8)
Moderate (36) 6.5 (9.1) 26.4 (17.7) 5.6 (12.1) 10.2 (11.7) 24.3 (19.9) 9.9 (16.8) 21.7 (14.9)
Severe (21) 5.2 (8.1) 55.4 (26.1)* 22.4 (26.1)* 9.8 (13.1) 27.4 (18.8)* 18.4 (15.9)* 33.5 (21.2)*
Stroke ES = 0.22 ES = 0.85 ES = 0.6 ES = 0.49 ES = 0.53 ES = 0.22 ES = 0.47
Mild (78) 9.3 (12.2) 51.6 (24.4) 18.0 (20.8) 11.7 (16.7) 90.0 (21.7) 97.7 (12.1) 43.1 (19.6)G
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Moderate (24) 12.2 (15.9) 71.2 (18.0)* 32.4 (31.9)* 21.3 (27.3) 100.0 (0.0)* 100.0 (0.0) 50.8 (16.5)
Osteoporosis ES = 0.49 ES = 1.44 ES = 0.53 ES = 0.7 ES = 1.1 ES = 0.3 ES = 1.31
Mild (41) 8.6 (11.8) 9.8 (16.1) 2.3 (11.4) 6.4 (11.2) 14.8 (24.2) 6.4 (13.7) 8.4 (13.3)
Moderate (27) 12.4 (13.3) 15.0 (11.6) 3.3 (6.2) 10.3 (14.6) 28.8 (19.0) 20.0 (19.8) 14.2 (10.9)
Severe (17) 15.6 (18.9) 35.7 (21.6)* 9.4 (17.5) 18.9 (28.3)* 42.7 (28.1)* 10.7 (15.2) 28.6 (19.8)*
Rheumatoid Arthritis ES = 0.88 ES = 3.73 ES = 3.98 ES = 0.17 ES = 4.18 ES = 5.85
Mild (5) 15.0 (12.7) 11.3 (21.8) 6.0 (13.4) 15.0 (13.7) 20.0 (18.7) 0.0 (.) 10.0 (9.6)
Moderate (16) 27.8 (20.2) 33.2 (17.6) 16.3 (15.9) 18.8 (15.1) 47.3 (20.3) 35.7 (14.3) 28.6 (13.8)
Severe (2) 30.0 (28.3) 84.4 (4.4)* 60.0 (14.1)* 12.5 (17.7) 90.0 (0.0)* --- 62.5 (5.9)*
Chronic Widespread Pain (CWP) ES = 1.23 ES = 0.69 ES = 0.62 ES = 0.47 ES = 0.13 ES = 0.90 ES = 1.18
Mild (8) 22.7 (12.8) 36.5 (18.0) 8.7 (14.1) 27.8 (21.4) 54.2 (21.9) 40.2 (20.5) 32.6 (17.0)
Moderate (21) 27.1 (20.4) 45.0 (22.9) 13.6 (16.5) 25.7 (24.3) 55.7 (27.1) 30.6 (20.9) 28.9 (15.5)
Severe (13) 47.3 (26.1)* 48.6 (17.0) 19.2 (20.2) 38.7 (24.7) 57.7 (31.7) 58.2 (19.5) 53.8 (18.7)*
Low Back Pain (LBP) ES = 0.03 ES = 0.56 ES = 0.62 ES = 0.13 ES = 0.47 ES = 0.37 ES = 0.87
Mild (42) 15.6 (18.3) 27.2 (23.6) 7.4 (12.7) 12.7 (19.3) 31.5 (29.6) 22.2 (34.2) 20.5 (18.8)
Moderate (44) 22.2 (19.8) 32.5 (20.8) 13.4 (16.1) 14.4 (17.1) 35.1 (26.2) 26.8 (32.0) 28.3 (21.0)
Severe (24) 15.1 (16.5) 40.4 (23.6) 17.5 (21.1)* 10.5 (14.5) 45.2 (27.9) 34.9 (34.5) 39.3 (25.9)*
Effect size (ES) coefficient among the extremes groups
* p < 0.05
Table 6: WHODAS-2 domain specific scores by disorder, according to severity level. (Continued)Garin et al. Health and Quality of Life Outcomes 2010, 8:51
http://www.hqlo.com/content/8/1/51
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Figure 2 WHODAS-2 scores for patients working (dots) and not working-sick leave (striped). Mean and 95% confidence interval is shown. Effect 
Size (ES) coefficient between working and not working-sick leave patients.
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only study in which stability of the WODAS-2 has been
assessed, presented excellent ICC coefficients (0.82-0.96)
on patients with inflammatory arthritis[15].
The WHODAS-2, as designed for covering disability,
measures the restrictions on daily life activities and social
participation, while the Short form-36 Health Survey
addresses patients' physical and mental health. The mod-
erate magnitude of the associations among the two
instruments is reflecting how the WHODAS-2 and the
SF-36 measure different aspects of related concepts (dis-
ability and HRQL, respectively). In fact, coefficients
found in previously published studies[23,15-18,20,21]
were fairly similar to ours. These findings support the
validity of WHODAS-2 to measure disability and its use
as an outcome which complements HRQL.
The WHODAS-2 is able to detect differences between
clinical-severity groups. Those patients classified as
severe reported worse disability scores than mild
patients, with a large difference for most of the health
conditions (66%), and a moderate difference for 25% of
them. Poor discrimination ability among severity groups
were found only for 3 of the WHODAS-2 domains ('Get-
t i n g  a l o n g  w i t h  p e o p l e ' ,  ' L i f e  a c t i v i t i e s  h o u s e h o l d '  a n d
'Life activities work or school'). Beside this, the instru-
ment detects differences between patients who were
working at the time of the study and those who were not
working due to their health condition. This is the first
time that such an ability is evaluated on the WHODAS-2,
and is specially remarkable when talking about disability,
probably more than being able to differentiate among
severity groups (which has also been shown in other
studies[15,16,22,23]).
Coefficients of change at 3 months were moderate or
low for all domains. However the WHODAS-2 sensitivity
to change may be under-estimated in our study due to the
MHADIE patients' characteristics and design, such as the
chronic profile of the conditions, and not being an evalu-
ative intervention study. Moreover, this pattern of low
improvement, also presented by the SF-36 (no physical
change and moderate mental improvement), an instru-
ment which has extensively demonstrated good respon-
siveness[52,21], is indicating the lack of a real great
improvement in our sample rather than a problem of
WHODAS-2 to detect change over time. In fact, a previ-
ous study has demonstrated how the WHODAS-2 is
quite responsive (ES = 0.65) when change is measured
after starting a treatment[21].
This study's results should be interpreted taking into
account some limitations. Firstly, the study was not spe-
cifically designed for evaluating responsiveness, since the
optimum design for this should include an intervention
which would produce a clear improvement or an event
closely related to deterioration. However, assuming that a
change in severity would be accompanied by a change in
self-perceived disability, patient improvement was mea-
sured indirectly due to the lack of a gold standard for dis-
ability change. Secondly, the interval for test-retest
evaluation is longer than the standard period used to
assess reproducibility. However, the selection strategy
applied assured the needed stability and ICC coefficients
showed agreement between evaluations. Moreover, it
should be noted that different WHODAS-2 linguistic
versions have been administered regarding the country
setting, but analyzed as a whole. To test the equivalence
Figure 3 Mean chage of the WHODAS-2 scores and the SF-36 component summaries, after 3 months. Mean change and 95% confidence in-
terval is shown. Effect Size (ES) responsiveness coefficient.
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of these versions, differential item functioning (DIF) anal-
ysis would be required [53]. However, it was not possible
in our study because of the sample design, where most of
the health conditions were recruited only in one country,
making impossible to differentiate the effect of these two
variables. Finally, other minor limitations are related to
version differences. The SF-36 v2 was used for Spanish
patients with psychiatric disorders but, as version 1 and 2
of the SF36 are quite similar , no impact on results was
expected. On the other hand, proxy versions used on
those patients unable to respond were negligible.
Conclusions
Despite some limitations, as discussed above, the results
provide considerable support to the WHODAS-2 utiliza-
tion as a common, international, and interdisciplinary
instrument to measure disability. Furthermore, it is of
special relevance because of being the only measure
based on the ICF biopsychosocial model. A strength of
the study is that the underlying latent structure originally
designed by developers has been confirmed for the first
time. This has moreover been conducted on an heteroge-
neous sample (different health conditions in several Euro-
pean countries), which gives even higher worth to results,
together with the assessment of its good metric proper-
ties. In conclusion, the WHODAS-2 is adequate to evalu-
ate disability in patients with chronic conditions, which
may help to eliminate barriers on developing policies, giv-
ing excellent evidence of these populations' needs.
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